Abstract
Giant axonal neuropathy (GAN) is an autosomal recessive disease caused by mutations in the GAN gene encoding gigaxonin. Patients develop a progressive sensorimotor neuropathy affecting peripheral nervous system (PNS) and central nervous system (CNS). Methods: In this multicenter observational retrospective study, we recorded French patients with GAN mutations, and 10 patients were identified. Mean age of patients was 9.7 years (2–18), eight patients were female (80%), and all patients met infant developmental milestones and had a family history of consanguinity. Mean age at disease onset was 3.3 years (1–5), and progressive cerebellar ataxia and distal motor weakness were the initial symptoms in all cases. Proximal motor weakness and bulbar symptoms appeared at a mean age of 12 years (8–14), and patients used a wheelchair at a mean age of 16 years (14–18). One patient died at age 18 years from aspiration pneumonia. In all cases, nerve conduction studies showed a mixed demyelinating and axonal sensorimotor neuropathy and MRI showed brain and cerebellum white matter abnormalities. Polyneuropathy and encephalopathy both aggravated during the course of the disease. Patients also showed a variety of associated findings, including curly hair (100% of cases), pes cavus (80%), ophthalmic abnormalities (30%), and scoliosis (30%). Five new GAN mutations were found, including the first synonymous mutation and a large intragenic deletion. Our findings expand the genotypic spectrum of GAN mutations, with relevant implications for molecular analysis of this gene, and confirm that GAN is an age-related progressive neurodegenerative disease involving PNS and CNS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Johnson-Kerner BL, Roth L, Greene JP, Wichterle H, Sproule DM (2014) Giant axonal neuropathy: an updated perspective on its pathology and pathogenesis. Muscle Nerve 50:467–476
Bomont P, Cavalier L, Blondeau F, Ben Hamida C, Belal S, Tazir M, Demir E, Topaloglu H, Korinthenberg R, Tüysüz B, Landrieu P, Hentati F, Koenig M (2000) The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet 26:370–374
Tazir M, Vallat JM, Bomont P, Zemmouri R, Sindou P, Assami S, Nouioua S, Hammadouche T, Grid D, Koenig M (2002) Genetic heterogeneity in giant axonal neuropathy: an Algerian family not linked to chromosome 16q24.1. Neuromuscul Disord 12:849–852
Bomont P, Ioos C, Yalcinkaya C et al (2003) Identification of seven novel mutations in the GAN gene. Hum Mutat 21:446
Bruno C, Bertini E, Federico A et al (2004) Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology 62:13–16
Demir E, Bomont P, Erdem S et al (2005) Giant axonal neuropathy: clinical and genetic study in six cases. J Neurol Neurosurg Psychiatry 76:825–832
Houlden H, Groves M, Miedzybrodzka Z et al (2007) New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy. J Neurol Neurosurg Psychiatry 78:1267–1270
Tazir M, Nouioua S, Magy L et al (2009) Phenotypic variability in giant axonal neuropathy. Neuromuscul Disord 19:270–274
Roth LA, Johnson-Kerner BL, Marra JD, LaMarca NH, Sproule DM (2014) The absence of curly hair is associated with a milder phenotype in giant axonal neuropathy. Neuromuscul Disord 24:48–55
Koichihara R, Saito T, Ishiyama A et al (2016) A mild case of giant axonal neuropathy without central nervous system manifestation. Brain Dev 38:350–353
Aharoni S, Barwick KE, Straussberg R, Harlalka et al (2016) Novel homozygous missense mutation in GAN associated with Charcot-Marie-Tooth disease type 2 in a large consanguineous family from Israel. BMC Med Genet 17:82
Normendez-Martínez MI, Monterde-Cruz L, Martínez R, Marquez-Harper M, Esquitin-Garduño N, Valdes-Flores M, Casas-Avila L, de Leon-Suarez VP, Romero-Díaz VJ, Hidalgo-Bravo A (2018) Two novel mutations in the GAN gene causing giant axonal neuropathy. World J Pediatr. 14:298–304
Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in Genie. J Comput Biol 4:311–323
Dogan RI, Getoor L, Wilbur WJ, Mount SM (2007) SplicePort: an interactive splice-site analysis tool. Nucleic Acids Res 35:W285–W291
Desmet FO, Hamroun D, Lalande M et al (2009) Human splicing finder: an online bio-neurogenetics informatics tool to predict splicing signals. Nucleic Acids Res 37:e67
Crehalet H, Latour P, Bonnet V et al (2010) U1 snRNA mis-binding: a new cause of CMT1B. Neurogenetics 11:13–19
Roth LA, Marra JD, LaMarca NH, Sproule DM (2015) Measuring disease progression in giant axonal neuropathy: implications for clinical trial design. J Child Neurol 30:741–748
Hoebeke C, Bonello-Palot N, Audic F et al (2018) Retrospective study of 75 children with peripheral inherited neuropathy: genotype-phenotype correlations. Arch Pediatr 25:452–458
Bacquet J, Stojkovic T, Boyer A et al (2018) Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. BMJ Open 8:e021632
Buysse K, Vergult S, Mussche S, Ceuterick-de Groote C, Speleman F, Menten B, Lissens W, van Coster R (2010) Giant axonal neuropathy caused by compound heterozygosity for a maternally inherited microdeletion and a paternal mutation within the GAN gene. Am J Med Genet A 152A:2802–2804
Boizot A, Talmat-Amar Y, Morrogh D et al (2014) The instability of the BTB-KELCH protein gigaxonin causes giant axonal neuropathy and constitutes a new penetrant and specific diagnostic test. Acta Neuropathol Commun 2:47
Johnson-Kerner BL, Ahmad FS, Diaz AG, Greene JP, Gray SJ, Samulski RJ, Chung WK, van Coster R, Maertens P, Noggle SA, Henderson CE, Wichterle H (2015) Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. Hum Mol Genet 24:1420–1431
Johnson-Kerner BL, Garcia Diaz A, Ekins S, Wichterle H (2015) Kelch Domain of gigaxonin interacts with intermediate filament proteins affected in giant axonal neuropathy. PLoS One 10:e0140157
Armao D, Bouldin TW, Bailey RM et al (2019) Advancing the pathologic phenotype of giant axonal neuropathy: early involvement of the ocular lens. Orphanet J Rare Dis 14:27
Mahammad S, Murthy SN, Didonna A, Grin B, Israeli E, Perrot R, Bomont P, Julien JP, Kuczmarski E, Opal P, Goldman RD (2013) Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation. J Clin Invest 123:1964–1975
Bailey RM, Armao D, Nagabhushan Kalburgi S, Gray SJ (2018) Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol Ther Methods Clin Dev:160–171
Competing interests
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was accepted and achieved under the ethical guidelines issued by our institutions for clinical studies. This study was in compliance with the Helsinki Declaration. All patients gave informed consent.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOC 52 kb)
Rights and permissions
About this article
Cite this article
Echaniz-Laguna, A., Cuisset, JM., Guyant-Marechal, L. et al. Giant axonal neuropathy: a multicenter retrospective study with genotypic spectrum expansion. Neurogenetics 21, 29–37 (2020). https://doi.org/10.1007/s10048-019-00596-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-019-00596-z